Nevertheless, in the whole cohort, most GBM patients, locating in the frontal lobe were MGMT promoter methylated (53.3%, 40/75), significantly higher than non-frontal lesions (36.7%, 58/158, P = 0.016), but the resection degree was not statistically different (GTR: 64.0% for frontal and 58.2% for non-frontal lesions, P = 0.401). Here, MGMT is linked to glioblastoma.